Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTEPAR vs EMVERM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Treatment of ascariasis (roundworm infection),Treatment of enterobiasis (pinworm infection)
Treatment of trichuriasis (whipworm infection),Treatment of enterobiasis (pinworm infection),Treatment of ascariasis (roundworm infection),Treatment of hookworm infections (Ancylostoma duodenale and Necator americanus),Off-label: Treatment of capillariasis, toxocariasis, and other helminth infections
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
Partially metabolized in the liver; some metabolites are excreted unchanged.
Primarily hepatic; metabolized by microsomal enzymes (CYP450) to major metabolite 2-aminomebendazole, which is less active; also undergoes further metabolism.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Approximately 90% bound to plasma proteins, primarily albumin.
~90-95% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water.
~1-2 L/kg; indicates extensive tissue distribution.
Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism.
Oral: ~22-40% due to first-pass metabolism; improved with food.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis.
No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%.
No adjustment for mild (Child-Pugh A) or moderate (Child-Pugh B) impairment. Avoid use in severe hepatic impairment (Child-Pugh C) due to increased risk of toxicity.
Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg.
Children ≥2 years: 100 mg orally twice daily for 3 days. Children <2 years: safety not established; use only if potential benefit outweighs risk.
Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment.
No specific adjustment required; use standard adult dosing. Monitor for adverse effects due to potential age-related renal or hepatic decline.
None.
None.
Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses.
Risk of neutropenia and agranulocytosis, especially with high doses or prolonged use,May cause bone marrow suppression; monitor blood counts in prolonged therapy,Hepatotoxicity reported; use caution in hepatic impairment,Seizures have occurred, particularly in patients with history of seizures,Not recommended in pregnancy (pregnancy category C); embryotoxic and teratogenic in animals
Hypersensitivity to piperazine; patients with pre-existing neurological disorders such as epilepsy.
Hypersensitivity to mebendazole or any component of the formulation,Absolute contraindication: Known hypersensitivity
No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs.
No significant food interactions; absorption is enhanced by fatty foods but not required for efficacy in enterobiasis. Avoid alcohol due to potential hepatotoxicity.
ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed.
FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed. Risk cannot be ruled out, especially in the first trimester.
Piperazine is excreted into breast milk in small amounts. The M/P ratio is not established. The American Academy of Pediatrics considers piperazine compatible with breastfeeding, but caution is advised due to potential adverse effects in nursing infants. Use only if benefits outweigh risks.
Excretion in human milk unknown. Caution should be exercised when administered to a nursing woman. M/P ratio not available.
No specific dose adjustments recommended during pregnancy. Piperazine pharmacokinetics may be altered due to increased plasma volume and renal clearance, but standard dosing is generally used. Monitor for efficacy and adverse effects.
No dose adjustment is recommended solely due to pregnancy, as pharmacokinetic changes are not well characterized. Use standard dosing: mebendazole 100 mg twice daily for 3 days for pinworm (or single 100 mg dose). For other indications, follow standard protocols.
ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives.
EMVERM (mebendazole) is poorly absorbed systemically, making it ideal for intraluminal helminth infections. Administer with fatty meal to enhance absorption when systemic effect (e.g., for trichinosis) is desired. Avoid in pregnancy (FDA Category C). Tablets may be chewed, swallowed, or crushed. Monitor for rare agranulocytosis, especially with concurrent metronidazole or high doses.
Take exactly as prescribed; complete full course even if symptoms improve.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Report any muscle weakness, tremors, or confusion to your doctor immediately.,For pinworm infection, all household members should be treated to prevent reinfection.,Practice strict hand hygiene and wash bed linens in hot water to reduce spread.
Take exactly as prescribed; a second course may be needed if reinfection occurs.,Tablets can be chewed, crushed, or swallowed whole with or without food.,Mebendazole works by preventing worms from absorbing sugar, causing their death.,Strict hand hygiene and laundering of bedding/clothing to prevent reinfection.,Treat all household members if pinworm outbreak; withhold treatment in pregnancy unless essential.,Notify provider if fever, sore throat, or unusual bleeding/bruising (agranulocytosis warning).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTEPAR vs EMVERM, answered by our medical review team.
ANTEPAR is a Anthelmintic that works by Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.. EMVERM is a Anthelmintic that works by Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTEPAR and EMVERM depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTEPAR is: Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.. The standard adult dose of EMVERM is: Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTEPAR and EMVERM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTEPAR is classified as Category C. ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. Fir. EMVERM is classified as Category C. FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at high doses. Human data are limited; therefore, use during pregnancy only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.